Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia

Technology appraisal guidance
Reference number: TA218
Published: 23 March 2011

Myelodysplastic syndromes - azacitidine: consultee and commentator comments on the ACD

Myelodysplastic syndromes - azacitidine: Celgene
Myelodysplastic syndromes - azacitidine: MDS UK Patient Support Group
Myelodysplastic syndromes - azacitidine: Royal College of Nursing
Myelodysplastic syndromes - azacitidine: Royal College of Pathologists and the British Society for Haematology
Myelodysplastic syndromes - azacitidine: Royal College of Physicians on behalf of NCRI/RCP/RCR/ACP/JCCO
Myelodysplastic syndromes - azacitidine: Department of Health
Myelodysplastic syndromes - azacitidine: Decision Support Unit review of Celgene's response to the post appeal ACD

This page was last updated: 16 February 2011